The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
1078153011 10781530 11 F 20160121 20160831 20150210 20160906 EXP US-GLAXOSMITHKLINE-A1070012A GLAXOSMITHKLINE 58.22 YR F Y 0.00000 20160906 OT US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
1078153011 10781530 1 PS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 29.3 NG/KG/MIN, 1.5 MG VIAL STRENGTH, 30,000 NG/ML CONCENTRATION U R614 20444 29.3 DF POWDER FOR INFUSION
1078153011 10781530 2 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 29.32 NG/KG/MIN (CONCENTRATION 30,000 NG/ML, PUMP RATE 76 ML/DAY, VIAL STRENGTH 1.5 MG), CO U U631 20444 POWDER FOR INFUSION
1078153011 10781530 3 SS FLOLAN EPOPROSTENOL SODIUM 1 27.78 NG/KG/MIN, (CONCENTRATION 30,000 NG/ML, PUMP RATE 72 ML/DAY, VIAL STRENGTH 1.5 MG), CO U V378 20444 27.78 DF POWDER FOR INFUSION
1078153011 10781530 4 SS FLOLAN EPOPROSTENOL SODIUM 1 26.2 DF, CO U V049 20444 26.2 DF POWDER FOR INFUSION
1078153011 10781530 5 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 25.5 NG/KG/MIN U V785 20444 POWDER FOR INFUSION
1078153011 10781530 6 SS FLOLAN EPOPROSTENOL SODIUM 1 UNK, CO U V785 20444 POWDER FOR INFUSION
1078153011 10781530 7 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 25.5 NG/KG/MIN U V785 20444 POWDER FOR INFUSION
1078153011 10781530 8 SS FLOLAN EPOPROSTENOL SODIUM 1 UNK, CO U Z606 20444 POWDER FOR INFUSION
1078153011 10781530 9 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 23.53 NG/KG/MIN, CO U Z880 20444 23.53 DF POWDER FOR INFUSION
1078153011 10781530 10 SS FLOLAN EPOPROSTENOL SODIUM 1 U 0 SOLUTION FOR INJECTION
1078153011 10781530 11 C LIDOCAINE. LIDOCAINE 1 U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
1078153011 10781530 1 Cor pulmonale chronic
1078153011 10781530 2 Pulmonary hypertension
1078153011 10781530 10 Pulmonary hypertension

Outcome of event

Event ID CASEID OUTC COD
1078153011 10781530 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
1078153011 10781530 Catheter site haemorrhage
1078153011 10781530 Catheter site inflammation
1078153011 10781530 Central venous catheterisation
1078153011 10781530 Cough
1078153011 10781530 Device breakage
1078153011 10781530 Diarrhoea
1078153011 10781530 Epistaxis
1078153011 10781530 Flushing
1078153011 10781530 Malabsorption
1078153011 10781530 Nasopharyngitis
1078153011 10781530 Night sweats
1078153011 10781530 Pain in jaw
1078153011 10781530 Paranasal sinus hypersecretion
1078153011 10781530 Pyrexia
1078153011 10781530 Respiratory tract congestion
1078153011 10781530 Rhinorrhoea
1078153011 10781530 Sinusitis
1078153011 10781530 Throat irritation
1078153011 10781530 Tooth fracture
1078153011 10781530 Viral infection

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
1078153011 10781530 1 20140110 0
1078153011 10781530 6 20140110 0
1078153011 10781530 7 20140110 0
1078153011 10781530 8 20140110 0